Research Type: Assessment

Cardiovascular Disease: Coronary Computed Tomographic Angiography

Jul 2012 | Assessment

Interventions of interest: Coronary computed tomographic angiography Coronary computed tomographic angiography (CCTA) is a minimally invasive radiological technique used to provide images of the heart and surrounding vessels. CCTA has been suggested as an alternative or useful complementary approach to other non-invasive methods of diagnosing coronary artery disease (CAD). Date of review: January 2009 For […]

PTSD: Service Dogs

Jan 1970 | Assessment

ICER has been commissioned to conduct an assessment of the cost-effectiveness of service dogs trained in tasks related to post-traumatic stress disorder (PTSD) based on findings from the largest examination to date on the impact of service dogs on PTSD conducted by the U.S. Department of Veterans Affairs (VA). For questions, please contact Meaghan Cummings, […]

High Cholesterol

Feb 2021 | Assessment

Interventions of interest: inclisiran (Leqvio®, Novartis) bempedoic acid (Nexletol®, Esperion Therapeutics) bempedoic acid/ezetimibe (Nexlizet™, Esperion Therapeutics) An independent appraisal committee voted that the evidence is not adequate to demonstrate a net health benefit of bempedoic acid over usual care for the entire population of eligible patients, but is adequate when focused on patients unable to […]

High Cholesterol: PCSK9s

Feb 2019 | Assessment

Interventions of Interest: alirocumab (Praluent®, Regeneron/Sanofi) evolocumab (Repatha®, Amgen) Cardiovascular disease (CVD) is the most common cause of death in the United States and approximately one third of American adults have CVD. Low density lipoprotein cholesterol (LDL) is a major modifiable risk factor for myocardial infarction, stroke, and death from cardiovascular disease. The use of […]

Prostate Cancer: Active Surveillance and Prostatectomy

Sep 2009 | Assessment

Prostate cancer is the second leading cause of cancer deaths and the seventh overall cause of death in men in the United States (Centers for Disease Control and Prevention, 2008). Given that most new cases are diagnosed at an early, localized stage, significant attention has been focused on understanding the risks and benefits of alternative […]

Hemophilia A

Oct 2020 | Assessment

Interventions of Interest: Factor VIII: Factor VIII concentrate is given intravenously, whether administered on-demand or prophylactically. Prophylaxis is administered multiple times per week, which is burdensome. Emicizumab (Hemlibra®, Genentech): a monoclonal antibody with dual targets that allow it to bridge activated factor IX and factor X, the role normally played by activated factor VIII in […]

Spinal Muscular Atrophy

Mar 2019 | Assessment

Treatments of Interest: onasemnogene abeparvovec (Zolgensma®, Novartis AG/AveXis) nusinersen (Spinraza®, Biogen) Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease. In its most common form, Type I SMA (~60% of cases), symptoms begin in infancy. Affected children never sit up, and they rapidly develop difficulty swallowing and breathing, eventually requiring feeding tubes and mechanical […]

Amyloidosis

Aug 2018 | Assessment

Interventions of Interest inotersen (Tegsedi®, Akcea Therapeutics) patisiran (Onpattro®, Alnylam Pharmaceuticals) ICER reviewed new therapies for the treatment of hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council voted unanimously that, despite the net health benefit, both inotersen and […]

Rheumatoid Arthritis

Mar 2017 | Assessment

2017 Interventions of Interest: TNF Inhibitors Adalimumab (Humira®, Abbvie) Certolizumab pegol (Cimzia®, UCB) Etanercept (Enbrel®, Amgen) Golimumab (Simponi®, Janssen) Infliximab (Remicade®, Janssen) CD20- Directed Cytolytic Antibody Rituximab (Rituxan®, Genentech) T Cell Inhibitor Abatacept (Orencia®, BMS) IL-6 Inhibitors Sarilumab (Kevzara®, Sanofi and Regeneron Pharmaceuticals) Tocilizumab (Actemra®, Genentech) JAK- Inhibitors Tofacitinib (Xeljanz®, Pfizer) Baricitinib (Olumiant®, Eli Lilly […]

Rheumatoid Arthritis

Dec 2019 | Assessment

Interventions of Interest: JAK- Inhibitors Baricitinib (Olumiant®, Eli Lilly and Co.) Tofacitinib (Xeljanz®, Pfizer) Upadacitinib (Rinvoq™, AbbVie) adalimumab (Humira®, AbbVie) Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults, affecting approximately 1.5 million Americans. RA is more common in women and may occur at any age, with peak incidence occurring at ages […]